Cargando…
Costs of care for persons with opioid dependence in commercial integrated health systems
BACKGROUND: When used in general medical practices, buprenorphine is an effective treatment for opioid dependence, yet little is known about how use of buprenorphine affects the utilization and cost of health care in commercial health systems. METHODS: The objective of this retrospective cohort stud...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142137/ https://www.ncbi.nlm.nih.gov/pubmed/25123823 http://dx.doi.org/10.1186/1940-0640-9-16 |
_version_ | 1782331732357283840 |
---|---|
author | Lynch, Frances L McCarty, Dennis Mertens, Jennifer Perrin, Nancy A Green, Carla A Parthasarathy, Sujaya Dickerson, John F Anderson, Bradley M Pating, David |
author_facet | Lynch, Frances L McCarty, Dennis Mertens, Jennifer Perrin, Nancy A Green, Carla A Parthasarathy, Sujaya Dickerson, John F Anderson, Bradley M Pating, David |
author_sort | Lynch, Frances L |
collection | PubMed |
description | BACKGROUND: When used in general medical practices, buprenorphine is an effective treatment for opioid dependence, yet little is known about how use of buprenorphine affects the utilization and cost of health care in commercial health systems. METHODS: The objective of this retrospective cohort study was to examine how buprenorphine affects patterns of medical care, addiction medicine services, and costs from the health system perspective. Individuals with two or more opioid-dependence diagnoses per year, in two large health systems (System A: n = 1836; System B: n = 4204) over the time span 2007–2008 were included. Propensity scores were used to help adjust for group differences. RESULTS: Patients receiving buprenorphine plus addiction counseling had significantly lower total health care costs than patients with little or no addiction treatment (mean health care costs with buprenorphine treatment = $13,578; vs. mean health care costs with no addiction treatment = $31,055; p < .0001), while those receiving buprenorphine plus addiction counseling and those with addiction counseling only did not differ significantly in total health care costs (mean costs with counseling only: $17,017; p = .5897). In comparison to patients receiving buprenorphine plus counseling, those with little or no addiction treatment had significantly greater use of primary care (p < .001), other medical visits (p = .001), and emergency services (p = .020). Patients with counseling only (compared to patients with buprenorphine plus counseling) used less inpatient detoxification (p < .001), and had significantly more PC visits (p = .001), other medical visits (p = .005), and mental health visits (p = .002). CONCLUSIONS: Buprenorphine is a viable alternative to other treatment approaches for opioid dependence in commercial integrated health systems, with total costs of health care similar to abstinence-based counseling. Patients with buprenorphine plus counseling had reduced use of general medical services compared to the alternatives. |
format | Online Article Text |
id | pubmed-4142137 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-41421372014-08-25 Costs of care for persons with opioid dependence in commercial integrated health systems Lynch, Frances L McCarty, Dennis Mertens, Jennifer Perrin, Nancy A Green, Carla A Parthasarathy, Sujaya Dickerson, John F Anderson, Bradley M Pating, David Addict Sci Clin Pract Research BACKGROUND: When used in general medical practices, buprenorphine is an effective treatment for opioid dependence, yet little is known about how use of buprenorphine affects the utilization and cost of health care in commercial health systems. METHODS: The objective of this retrospective cohort study was to examine how buprenorphine affects patterns of medical care, addiction medicine services, and costs from the health system perspective. Individuals with two or more opioid-dependence diagnoses per year, in two large health systems (System A: n = 1836; System B: n = 4204) over the time span 2007–2008 were included. Propensity scores were used to help adjust for group differences. RESULTS: Patients receiving buprenorphine plus addiction counseling had significantly lower total health care costs than patients with little or no addiction treatment (mean health care costs with buprenorphine treatment = $13,578; vs. mean health care costs with no addiction treatment = $31,055; p < .0001), while those receiving buprenorphine plus addiction counseling and those with addiction counseling only did not differ significantly in total health care costs (mean costs with counseling only: $17,017; p = .5897). In comparison to patients receiving buprenorphine plus counseling, those with little or no addiction treatment had significantly greater use of primary care (p < .001), other medical visits (p = .001), and emergency services (p = .020). Patients with counseling only (compared to patients with buprenorphine plus counseling) used less inpatient detoxification (p < .001), and had significantly more PC visits (p = .001), other medical visits (p = .005), and mental health visits (p = .002). CONCLUSIONS: Buprenorphine is a viable alternative to other treatment approaches for opioid dependence in commercial integrated health systems, with total costs of health care similar to abstinence-based counseling. Patients with buprenorphine plus counseling had reduced use of general medical services compared to the alternatives. BioMed Central 2014 2014-08-14 /pmc/articles/PMC4142137/ /pubmed/25123823 http://dx.doi.org/10.1186/1940-0640-9-16 Text en Copyright © 2014 Lynch et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. |
spellingShingle | Research Lynch, Frances L McCarty, Dennis Mertens, Jennifer Perrin, Nancy A Green, Carla A Parthasarathy, Sujaya Dickerson, John F Anderson, Bradley M Pating, David Costs of care for persons with opioid dependence in commercial integrated health systems |
title | Costs of care for persons with opioid dependence in commercial integrated health systems |
title_full | Costs of care for persons with opioid dependence in commercial integrated health systems |
title_fullStr | Costs of care for persons with opioid dependence in commercial integrated health systems |
title_full_unstemmed | Costs of care for persons with opioid dependence in commercial integrated health systems |
title_short | Costs of care for persons with opioid dependence in commercial integrated health systems |
title_sort | costs of care for persons with opioid dependence in commercial integrated health systems |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142137/ https://www.ncbi.nlm.nih.gov/pubmed/25123823 http://dx.doi.org/10.1186/1940-0640-9-16 |
work_keys_str_mv | AT lynchfrancesl costsofcareforpersonswithopioiddependenceincommercialintegratedhealthsystems AT mccartydennis costsofcareforpersonswithopioiddependenceincommercialintegratedhealthsystems AT mertensjennifer costsofcareforpersonswithopioiddependenceincommercialintegratedhealthsystems AT perrinnancya costsofcareforpersonswithopioiddependenceincommercialintegratedhealthsystems AT greencarlaa costsofcareforpersonswithopioiddependenceincommercialintegratedhealthsystems AT parthasarathysujaya costsofcareforpersonswithopioiddependenceincommercialintegratedhealthsystems AT dickersonjohnf costsofcareforpersonswithopioiddependenceincommercialintegratedhealthsystems AT andersonbradleym costsofcareforpersonswithopioiddependenceincommercialintegratedhealthsystems AT patingdavid costsofcareforpersonswithopioiddependenceincommercialintegratedhealthsystems |